Patents by Inventor Jason Tierney

Jason Tierney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vasopressin receptor antagonists and products and methods related thereto
    Patent number: 11858943
    Abstract: Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein A, B, G, R1, R1b, R1c, R2 and X are as defined herein.
    Type: Grant
    Filed: October 13, 2021
    Date of Patent: January 2, 2024
    Assignee: NEUMORA THERAPEUTICS, INC.
    Inventors: Robert M. Jones, Mariangela Urbano, Gary Brandt, David Hardick, Chris Knight, Jason Tierney
  • VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO
    Publication number: 20230093235
    Abstract: Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein A, B, G, R1, R1b, R1c, R2 and X are as defined herein.
    Type: Application
    Filed: October 13, 2021
    Publication date: March 23, 2023
    Inventors: Robert M. Jones, Mariangela Urbano, Gary Brandt, David Hardick, Chris Knight, Jason Tierney
  • RHO KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20220388998
    Abstract: Provided herein are certain inhibitors of ROCK (rho-kinases or rho-associated kinases), which are useful as medicament, for the treatment Huntington's disease in particular.
    Type: Application
    Filed: June 26, 2020
    Publication date: December 8, 2022
    Inventors: Michel C. Maillard, Matthew R. Lee, Celia Dominguez, Michael Barnes, Alan F. Haughan, Tammy Ladduwahetty, Christopher A. Luckhurst, Andrew J. Stott, Jason Tierney
  • PCSK9 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20220220122
    Abstract: The invention relates to novel heteroaryl compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cardiovascular diseases, and methods treating sepsis or septic shock, using the novel heterocyclic compounds disclosed herein.
    Type: Application
    Filed: December 20, 2021
    Publication date: July 14, 2022
    Inventors: Michael H. SERRANO-WU, Mark CHAMBERS, Erica GOLDSMITH, Jason TIERNEY, Karamjit JANDU, David CLARK, Paul HINCHLIFFE
  • PCSK9 inhibitors and methods of use thereof
    Patent number: 11248001
    Abstract: The invention relates to novel heteroaryl compounds of Formula (I) and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cardiovascular diseases, and methods treating sepsis or septic shock, using the novel heterocyclic compounds disclosed herein.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: February 15, 2022
    Assignee: AstraZeneca AB
    Inventors: Michael H. Serrano-Wu, Mark Chambers, Erica Goldsmith, Jason Tierney, Karamjit Jandu, David Clark, Paul Hinchliffe
  • Vasopressin receptor antagonists and products and methods related thereto
    Patent number: 11186577
    Abstract: Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein A, B, G, R1, R1b, R1c, R2 and X are as defined herein.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: November 30, 2021
    Assignee: BLACKTHORN THERAPEUTICS, INC.
    Inventors: Robert M. Jones, Mariangela Urbano, Gary Brandt, David Hardick, Chris Knight, Jason Tierney
  • VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO
    Publication number: 20210317126
    Abstract: Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein Q1, Q2, Q3, R2a, R2b, R3 and X are as defined herein.
    Type: Application
    Filed: March 5, 2021
    Publication date: October 14, 2021
    Inventors: Robert M. Jones, Mariangela Urbano, Gary Brandt, Mark Chambers, David Hardick, Chris Knight, Jason Tierney, Chris Lock
  • PCSK9 Inhibitors and Methods of Use Thereof
    Publication number: 20200291041
    Abstract: The invention relates to novel heteroaryl compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cardiovascular diseases, and methods treating sepsis or septic shock, using the novel heterocyclic compounds disclosed herein.
    Type: Application
    Filed: January 16, 2020
    Publication date: September 17, 2020
    Inventors: Michael H. Serrano-Wu, Mark Chambers, Erica Goldsmith, Jason Tierney, Karamjit Jandu, David Clark, Paul Hinchliffe
  • Vasopressin receptor antagonists and products and methods related thereto
    Patent number: 10538530
    Abstract: Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein Q1, Q2, Q3, R2a, R2b, R3 and X are as defined herein.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: January 21, 2020
    Assignee: BlackThorn Therapeutics, Inc.
    Inventors: Robert M. Jones, Mariangela Urbano, Gary Brandt, Mark Chambers, David Hardick, Chris Knight, Jason Tierney, Chris Lock
  • VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO
    Publication number: 20190169202
    Abstract: Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein Q1, Q2, Q3, R2a, R2b, R3 and X are as defined herein.
    Type: Application
    Filed: September 5, 2018
    Publication date: June 6, 2019
    Inventors: Robert M. Jones, Mariangela Urbano, Gary Brandt, Mark Chambers, David Hardick, Chris Knight, Jason Tierney, Chris Lock
  • VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO
    Publication number: 20190048013
    Abstract: Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: wherein A, B, G, R1, R1b, R1c, R2 and X are as defined herein.
    Type: Application
    Filed: June 5, 2018
    Publication date: February 14, 2019
    Inventors: Robert M. Jones, Mariangela Urbano, Gary Brandt, David Hardick, Chris Knight, Jason Tierney
  • 1-[(indol-3-yl)carbonyl]piperazine derivatives
    Patent number: 7304064
    Abstract: The present invention relates to 1-[(indol-3-yl)carbonyl]piperazine derivative according to the general formula I or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising said 1-[(indol-3-yl)carbonyl]piperazine derivatives, and to the use of these derivatives in the treatment of pain, such as peri-operative pain, chronic pain neuropathic pain, cancer pain, and pain and spasticity associated with multiple sclerosis.
    Type: Grant
    Filed: June 13, 2003
    Date of Patent: December 4, 2007
    Assignee: N.V. Organon
    Inventors: Phillip Martin Cowley, Wilson Caulfield, Jason Tierney, James Cairns, Julia Adam-Worrall, Mark York
  • 1-[(Indol-3-yl)carbonyl]piperazine derivatives
    Publication number: 20050250760
    Abstract: The present invention relates to 1-[(indol-3-yl)carbonyl]piperazine derivative according to the general formula I or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising said 1-[(indol-3-yl)carbonyl]piperazine derivatives, and to the use of these derivatives in the treatment of pain, such as peri-operative pain, chronic pain neuropathic pain, cancer pain, and pain and spasticity associated with multiple sclerosis.
    Type: Application
    Filed: June 13, 2003
    Publication date: November 10, 2005
    Inventors: Phillip Cowley, Wilson Caulfield, Jason Tierney, James Cairns, Julia Adam-Worrall, Mark York